Key result
The polymer-free BioFreedom stent demonstrated rapid healing, with median neointimal strut coverage reaching 99.6% at nine months and a major adverse cardiac event rate of 4.0%.
RCT (n=104)
The polymer-free biolimus A9-coated coronary stent demonstrates rapid neointimal strut coverage, reaching 99.6% at 9 months, with a low rate of major adverse cardiac events.
Answers are grounded in this paper and cite their sources.
Supports polymer-free stent use where rapid healing is prioritized; extends RCT evidence on biolimus-eluting platforms.
AIMS: This study aimed to establish the early healing and neointimal transformation profile of the new polymer-free BioFreedom stent through sequential optical coherence tomography (OCT) within the first nine months following stent implantation. METHODS AND RESULTS: We randomly assigned 104 BFS recipients to one of five groups with angiography and OCT follow-up at 1, 2, 3, 4, or 5 months, together with another follow-up for all at nine months. The primary endpoint was the degree of OCT-detected strut coverage at nine months. From 1, 2, 3, 4, and 5 months, median neointimal strut coverage increased from 85.8, 87.0, 88.6, 96.8 to 97.1%, respectively, to 99.6% (IQR 98.2-99.9) at nine months. At nine months, median percent neointimal volume was 13.0% and angiographic late lumen loss was 0.21±0.30 mm. Major adverse cardiac events (MACE) were limited to one non-cardiac death, one non-ST-elevation myocardial infarction not related to BFS, and two target lesion revascularisations without stent thrombosis (MACE rate 4.0%). CONCLUSIONS: Neointimal strut coverage of the BFS was rapid and the BFS was shown to be clinically safe and effective.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) conducted an RCT in Coronary artery disease (n=104). Polymer-free biolimus A9-coated coronary stent (BioFreedom) vs. Different OCT follow-up timing groups (1, 2, 3, 4, or 5 months) was evaluated on Degree of OCT-detected strut coverage at nine months. The polymer-free BioFreedom stent demonstrated rapid healing, with median neointimal strut coverage reaching 99.6% at nine months and a major adverse cardiac event rate of 4.0%.
Synapse has enriched 10 related papers. Consider them for comparative context: